Abilify Maintena is an antipsychotic medication used for the treatment of schizophrenia [1]. It is administered as an intramuscular injection [1].
What is Abilify Maintena's active ingredient?
The active ingredient in Abilify Maintena is aripiprazole [1]. Aripiprazole is also the active ingredient in the oral formulation of Abilify [2].
How is Abilify Maintena administered and for how long?
Abilify Maintena is given as an intramuscular injection by a healthcare professional [1]. Dosing typically involves an initial dose followed by monthly injections [1]. The duration of treatment depends on the individual's condition and response to the medication [1].
What are the common side effects of Abilify Maintena?
Common side effects associated with Abilify Maintena include injection site reactions, weight gain, headache, insomnia, and akathisia (a feeling of inner restlessness and inability to stay still) [1]. More serious potential side effects exist and should be discussed with a healthcare provider [1].
What is the difference between Abilify Maintena and oral Abilify?
The primary difference lies in their administration. Abilify Maintena is a long-acting injectable formulation, meaning it is administered once a month. Oral Abilify is taken daily by mouth [1][2]. Long-acting injectables may offer advantages in adherence for some patients [3].
When does Abilify Maintena's patent expire?
Information regarding specific patent expiry dates for Abilify Maintena can be found on drug patent tracking websites. DrugPatentWatch.com tracks patent information for various medications, including Abilify Maintena [4].
Are there generic versions of Abilify Maintena?
The availability of generic versions of long-acting injectable medications like Abilify Maintena can be complex and depends on patent expirations and regulatory approvals. Generic versions of oral aripiprazole are available [2].
What clinical data supports Abilify Maintena's use?
Clinical trials have demonstrated the efficacy of Abilify Maintena in maintaining symptom control in patients with schizophrenia [1]. Studies have assessed its effectiveness in reducing relapse rates and improving overall functioning [1].
What is the mechanism of action for aripiprazole in Abilify Maintena?
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors [1]. This mechanism is thought to help regulate dopamine and serotonin activity in the brain, which are implicated in the symptoms of schizophrenia [1].
What are the risks associated with Abilify Maintena?
Potential risks include serious side effects such as tardive dyskinesia (involuntary movements), neuroleptic malignant syndrome (a rare but serious reaction), metabolic changes (e.g., increased blood sugar, cholesterol), and an increased risk of stroke in elderly patients with dementia-related psychosis [1].
Sources:
[1] https://www.abilifyMaintena.com/
[2] https://www.abilify.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907551/
[4] https://drugpatentwatch.com/